{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T13:16:27Z","timestamp":1721826987114},"reference-count":39,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Mehr als 20% der Patienten mit idiopathischem Parkinson-Syndrom (IPS)\n                    entwickeln Psychosen. Am h\u00e4ufigsten sind visuelle Halluzinationen. Bei\n                    der Entwicklung der Psychosen scheinen die Pathogenese der Parkinson-Erkrankung\n                    sowie ihre Dauer ebenso eine Rolle zu spielen wie modulierende Effekte der\n                    dopaminergen Therapie. Beim Therapiemanagement steht neben allgemeinen\n                    Ma\u00dfnahmen zun\u00e4chst die Anpassung der dopaminergen Therapie im\n                    Vordergrund. Dies kann zu einer Gratwanderung werden zwischen Besserung der\n                    Halluzinationen und Verschlechterung der Motorik. Bei unzureichendem Erfolg kann\n                    eine antipsychotische Therapie notwendig werden \u2013 dabei ist die Auswahl\n                    auf sehr wenige Antipsychotika beschr\u00e4nkt, um nicht ernsthafte\n                    motorische Verschlechterungen zu riskieren. In der vorliegenden Arbeit wurden\n                    basierend auf dem aktuellen Stand der Literatur sowie empirischen\n                    Experten-basierten Erfahrungen aus dem klinischen Alltag relevante Aspekte zu\n                    Halluzinationen bei IPS-Patienten in der Praxis zusammengefasst und Empfehlungen\n                    zum Therapiemanagement erarbeitet.<\/jats:p>","DOI":"10.1055\/a-1670-7111","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:20:31Z","timestamp":1638231631000},"page":"456-464","source":"Crossref","is-referenced-by-count":2,"title":["Halluzinationen bei Patienten mit idiopathischem\n                    Parkinson-Syndrom"],"prefix":"10.1055","volume":"90","author":[{"given":"Daniel","family":"Weiss","sequence":"additional","affiliation":[{"name":"Neurologische Klinik mit Schwerpunkt Neurodegenerative Erkrankungen und\n                    Hertie-Institut f\u00fcr Klinische Hirnforschung,\n                    Universit\u00e4tsklinikum T\u00fcbingen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie mit Klinischer Neurophysiologie,\n                    Medizinisch Hochschule Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Klostermann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie mit Experimenteller Neurologie,\n                    Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Campus Benjamin\n                    Franklin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Weise","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Schmerztherapie und Schlafmedizin,\n                    Asklepios Fachklinikum Stadtroda, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten E.","family":"Zeuner","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Universit\u00e4tsklinikum\n                    Schleswig-Holstein, Campus Kiel, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Reichmann","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Neurologie,\n                    Universit\u00e4tsklinikum Carl Gustav Carus Dresden,\n                    Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00702-015-1400-x","article-title":"Psychosis in Parkinson\u2019s disease: identi\ufb01cation, prevention and\n                    treatment","volume":"123","author":"J Levin","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.parkreldis.2013.06.005","article-title":"Burden and health-related quality of life among caregivers of Brazilian\n                    Parkinson\u2019s disease patients","volume":"19","author":"F J Carod-Artal","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","article-title":"Treatment of psychosis and dementia in Parkinson\u2019s disease","volume":"16","author":"J G Goldman","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.25003","article-title":"Psychosis in Parkinson\u2019s disease without dementia: common and comorbid\n                    with other non-motor symptoms","volume":"27","author":"A H Lee","year":"2012","journal-title":"Mov Disord"},{"key":"ref5","first-page":"1","article-title":"Parkinson\u2019s disease and psychoses","volume":"29","author":"J V Bizzarri","year":"2015","journal-title":"Neuropsychiatr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson\u2019s\n                    disease","volume":"43","author":"C G Goetz","year":"1993","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.parkreldis.2013.06.006","article-title":"High rates and the risk factors for emergency room visits and hospitalization in\n                    Parkinson\u2019s disease","volume":"19","author":"A Hassan","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"ref8","first-page":"28","article-title":"Differenzialdiagnose und Therapie von Halluzinationen bei\n                    Parkinson-Syndromen","volume":"21","author":"D Wei\u00df","year":"2019","journal-title":"InFo Neurologie+Psychiatrie"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an\n                    NINDS, NIMH work group","volume":"22","author":"B Ravina","year":"2007","journal-title":"Mov Disord"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.02.014","article-title":"Ocular and visual disorders in Parkinson\u2019s disease: Common but\n                    frequently overlooked","volume":"40","author":"M S Ekker","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/mds.23835","article-title":"Visual plus nonvisual hallucinations in Parkinson\u2019s disease: development\n                    and evolution over 10 years","volume":"26","author":"C G Goetz","year":"2011","journal-title":"Mov Disord"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \u201ebenign hallucinations\u201c in Parkinson\n                    disease","volume":"63","author":"C G Goetz","year":"2006","journal-title":"Arch Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.22132","article-title":"Antipsychotic medication treatment for mild hallucinations in\n                    Parkinson\u2019s disease: Positive impact on long-term worsenin","volume":"23","author":"C G Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"D H Ffytche","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ane.13380","article-title":"Risk factors for minor hallucinations in Parkinson\u2019s disease","volume":"143","author":"S Omoto","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","article-title":"Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients,\n                    even from the premotor phase","volume":"31","author":"J Pagonabarraga","year":"2016","journal-title":"Mov Disord"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor\n                    complications from sub-Saharan Africa","volume":"137","author":"R Cilia","year":"2014","journal-title":"Brain"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neurol.2018.07.005","article-title":"Hyperdopaminergic behavioral spectrum in Parkinson\u2019s disease: A\n                    review","volume":"174","author":"M Bereau","year":"2018","journal-title":"Rev Neurol (Paris)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease:\n                    filling the bench-to-bedside gap","volume":"9","author":"P Calabresi","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"N J Diederich","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder\n                    Society Criteria","volume":"32","author":"G U Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ene.12022","article-title":"EFNS\/MDS-ES recommendations for the diagnosis of Parkinson\u2019s\n                    disease","volume":"20","author":"A Berardelli","year":"2013","journal-title":"Eur J Neurol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.parkreldis.2012.10.013","article-title":"Pathology and temporal onset of visual hallucinations, misperceptions and family\n                    misidentification distinguishes dementia with Lewy bodies from\n                    Alzheimer\u2019s disease","volume":"19","author":"T J Ferman","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies","volume":"89","author":"I G McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26164","article-title":"Changing gears \u2013 DBS for dopaminergic desensitization in\n                    Parkinson\u2019s disease?","author":"D Weiss","year":"2021","journal-title":"Ann Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090\n                    patients","volume":"67","author":"D Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s Disease with Early Motor\n                    Complications","volume":"368","author":"WM M Schuepbach","year":"2013","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and Management of Neuropsychiatric Symptoms in Parkinson\u2019s\n                    Disease","volume":"32","author":"C Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of\n                    quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s\n                    disease","volume":"20","author":"W G Ondo","year":"2005","journal-title":"Mov Disord"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"M Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a\n                    randomised, placebo-controlled phase 3 trial","volume":"383","author":"J Cummings","year":"2014","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/mds.27488","article-title":"Pimavanserin for Parkinson\u2019s Disease psychosis: Effects stratified by\n                    baseline cognition and use of cognitive-enhancing medications","volume":"33","author":"A J Espay","year":"2018","journal-title":"Mov Disord"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","article-title":"Long-term evaluation of open-label pimavanserin safety and tolerability in\n                    Parkinson\u2019s disease psychosis","volume":"77","author":"C G Ballard","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1017\/S1352465804001626","article-title":"A cognitive behavioural framework for the treatment of distressing visual\n                    hallucinations in older people","volume":"32","author":"D Collerton","year":"2004","journal-title":"Behav Cogn Psychother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","article-title":"Behavioural outcomes of subthalamic stimulation and medical therapy versus\n                    medical therapy alone for Parkinson\u2019s disease with early motor\n                    complications (EARLYSTIM trial): secondary analysis of an open-label randomised\n                    trial","volume":"17","author":"E Lhomm\u00e9e","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s Disease with Early Motor\n                    Complications","volume":"368","author":"WM M Schuepbach","year":"2013","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.26827","article-title":"Neuropsychological outcomes from constant current deep brain stimulation for\n                    Parkinson\u2019s disease","volume":"32","author":"A I Troster","year":"2017","journal-title":"Movement disorders"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(08)70114-5","article-title":"Neuropsychological and psychiatric changes after deep brain stimulation for\n                    Parkinson\u2019s disease: a randomised, multicentre study","volume":"7","author":"K Witt","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicpaone as an adjunct to levodopa in patients with Parkinson\u2019s disease\n                    and end-of-dose motor fluctuations: a randomised, double-blind, controlled\n                    trial","volume":"15","author":"J J Ferreira","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1670-7111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T19:51:23Z","timestamp":1719517883000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1670-7111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1670-7111","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]}}}